Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

About this update from Silexion Therapeutics Corp

Significant advancements in preclinical pipeline for SIL204, with groundbreaking data demonstrating efficacy against both primary tumors and metastases in orthotopic models; strengthened financial position with over $9 million gross funds raised in Q1 2025 GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on recent business developments. “The first quarter of 2025 highlighted our continued clinical traction and saw a number of major developments for Silexion, marked by strong preclinical data from our SIL204 program and successful financing activities that strengthened our balance sheet,” said Ilan Hadar, Chairman and CEO of Silexion. “Our latest orthotopic model data demonstrated SIL204’s ability to significantly reduce both primary tumor burden and metastatic spread when administered systemically, representing a potential paradigm shift in treating KRAS-driven cancers. Building on this success, we unveiled our expanded dual-route development strategy for SIL204, positioning us to potentially address both primary tumors and metastases in challenging oncology indications. With our enhanced financial position and strategic collaborations announced in the recent weeks, we believe we are well-positioned to advance our pipeline toward clinical development.” Recent Milestones & Business Highlights: First Quarter 2025 Financial Result Highlights: About Silexion Therapeutics Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company’s first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The Company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit:  https://silexion.com Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion’s business strategy, and in particular, its dual-route development strategy for SIL204, business collaboration with Catalent, and plans to initiate further studies and make regulatory submissions as part of its pipeline toward clinical development, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of Silexion’s success in completing preclinical studies and initiating clinical trials; (ii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. * Net of 421 treasury shares held by the Company as of March 31, 2025 and December 31, 2024 * Represents an amount less than $1 ** All share and per share amounts for the three months ended March 31, 2024 have been retroactively adjusted to reflect a 1-for-9 reverse share split that was effected on November 29, 2024 For More Financial Information: For a comprehensive understanding of the Company’s financial reports and related management’s discussion and analysis for the subject periods, please review the Company’s quarterly report on Form 10-Q for the quarter ended   March 31, 2025, available under the Company's EDGAR profile at https://www.sec.gov/edgar Company Contact Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO [email protected] Capital Markets & IR Contact Arx Capital Markets North American Equities Desk [email protected]

View stock analysis, news, and events for Silexion Therapeutics Corp